Building information modeling beam. Does it mean anything to you. What if I told you it is one of the skill that can help you compete and fast track through your career making you instantly employable placing you ahead of hundreds of graduates.a skill many architectural and engineering students heard about but few truly explore and it changed my life. A very good afternoon ladies and gentlemen. My name is Iwan Feros and I just graduated few months in August at from UTM Sander.Not too long ago, I was where m ...

Thank you. So when I was 19, I was in Montreal. I was an undergrad student and I managed to get sick with the flu.So I sat down and I Googled, "Is flu going to kill me?" And Google Google brought up Wikipedia. Wikipedia said no. So, I stayed at home for 3 days eating my typical diet of ramen and water and uh didn't get better.So, I decided to go to the hospital. Now, has anyone here been to a hospital or an emergency room. Raise of hands.So, who thought it was a really good use of their time. Very efficient ...

قبل كم سنه فقدت شخص عزيز علي بديت وراها افكر هوايه افكر وافكر 24 ساعه صار عندي خوف بديت احس هذا ياثر على صحتي صرت اتعب طول اليوم صار عندي شد عضلي رح الطبيب قال لي عندك شيء اسمه انكزايتي شنو يقصد؟ رحت بحثت حتى اقدر افهم نفسي اكثر لقيت معلومه غريبه اول مره اقراها هاي المعلومه تقول انه داخلنا اكو ثلاث اشخاص شخص اناني يعبر عن رغباته باي طريقه ممكنه شخص ملتزم بالقوانين الدين والاخلاق والشخص الثالث اللي هو يحاول يلقى الحل الامثل ويوازن بيناتهم الشخص الاول هو الاد او الهو الشخص الثاني هو السوبر ايجو او الانا العلي ...

Core Insights - BioStem Technologies, Inc. has completed patient enrollment for a clinical trial comparing BioREtain® Amnion Chorion (BR-AC) to standard care for non-healing diabetic foot ulcers (DFUs) [2][3] - The BR-AC-DFU-101 study aims to evaluate the effectiveness of BR-AC in achieving complete wound closure over a 12-week period [3][5] - Topline results from the study are expected in Q4 2025, with the trial initiated in Q4 2024 across 11 sites in the U.S. [3][4] Company Overview - BioStem Technologies focuses on developing, manufacturing, and commercializing placental-derived products for advanced wound care [2][10] - The company utilizes a proprietary BioREtain processing method that preserves the natural properties of perinatal tissue [8][10] - BioStem's quality management systems are accredited by the American Association of Tissue Banks and adhere to Good Tissue Practices and Good Manufacturing Processes [11] Clinical Trial Details - The primary objective of the BR-AC-DFU-101 study is to determine if the combination of standard care and BR-AC leads to a higher probability of complete wound closure compared to standard care alone [5] - Secondary outcome measures include comparing treatment group differences in wound closure rates, wound area, and volume [7] - The study has enrolled 71 patients, exceeding the initial target of 60 [3][4] Market Context - Diabetic foot ulcers affect approximately 15% of individuals with diabetes, with 6% requiring hospitalization due to complications [5] - The economic burden of DFUs in the U.S. is significant, with annual treatment costs estimated between $9 billion and $13 billion [6] - In 2023, 2.2 million patients received treatment for DFUs, with numbers projected to rise [6]

Core Insights - Tempus AI reported $193.8 million in Genomics revenues for Q1 2025, marking an increase of nearly 89% year over year, driven by a 20% growth in oncology test volumes and higher average revenue per test due to increased Medicare reimbursement rates [1][8] - The company is set to launch a new liquid biopsy assay, xM for treatment response monitoring, which will track changes in tumor fraction during immune-checkpoint inhibitor therapies, potentially influencing treatment decisions [2] - Tempus is also preparing to launch its first whole-genome sequencing test, Xh, aimed at detecting clinically relevant variants in hematological oncology by next year [3] - A companion diagnostic test is being developed in collaboration with Verastem Oncology, leveraging Tempus' FDA-approved xT CDx assay in clinical trials for ovarian cancer treatment [4] Industry Updates - Guardant Health reported a 20% year-over-year growth in oncology revenues, with a 25% increase in test volumes, and launched a hereditary cancer test [5] - Exact Sciences is experiencing strong international adoption of its Oncotype DX genomic test and has launched Cologuard Plus, which is expected to reduce false positives significantly [6] Financial Performance - Tempus AI shares have increased by 105.3% year to date, outperforming the industry average growth of 28% [7] - The company is trading at a forward Price-to-Sales ratio of 8.60X, compared to the industry average of 6.02X [9] - The Zacks Consensus Estimate for Tempus AI's 2025 earnings has been trending upward over the past 90 days, indicating positive market sentiment [11]

If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth ?Pfizer (NYSE: PFE ) is arguably the biggest victim of the radical new healthcare policies being brought about by the Trump administration, and in my view, this means that its dividend - currently yielding >7% perTh ...

Core Viewpoint - Oscar Health is positioned as a contrarian investment opportunity in the health insurance sector, demonstrating strong growth and profitability, particularly in light of potential regulatory changes that could expand its market significantly [1][15]. Company Overview and Q1 2025 Performance - Oscar Health is a tech-native health insurer focusing on individual and family plans through ACA exchanges, currently operating in 18 states and insuring approximately 2 million members, representing about 1 in every 13 ACA enrollees nationwide [4]. - In Q1 2025, Oscar reported $275.3 million in net income, a significant increase from $177.4 million a year prior, with total revenue reaching $3.05 billion, reflecting a robust 42% year-over-year growth [5]. - The company achieved a record-low SG&A ratio of 15.8%, down from 18.4%, indicating improved operational efficiency under new leadership [6]. Market Opportunity Analysis - The introduction of the Choose Medicare Act proposes a Medicare Part E public option, which could significantly increase Oscar's addressable market, potentially tripling it if the legislation passes [10]. - Oscar's digital infrastructure and technology position it well to capitalize on the expected influx of consumers seeking coverage through public marketplaces [10]. Valuation Discussion - Oscar trades at 14 times projected 2027 earnings, which is considered a bargain given its high double-digit revenue growth [11]. - The company's market cap of $4.8 billion is less than 50% of its current annual revenue, suggesting a valuation disconnect compared to traditional insurers [11]. Investment Considerations - The risk-reward profile favors buyers, with the potential for Oscar's valuation to increase significantly if the public option is realized, transforming it from a $5 billion to a $15 billion company within 18 months [13]. - Even without the Medicare Part E, Oscar's compelling growth metrics and operational improvements make it an attractive investment opportunity [13][15]. - The market currently undervalues Oscar as a traditional insurer, while it operates as a technology company in the insurance space, creating a unique investment opportunity [14].

Please welcome Jotina [Applause] Buck. I'm sitting in my car in my garage and for a solid 30 minutes I don't move. You know that moment when you pull into the garage after a long day of work and instead of getting out, you just sit there.Yeah, that's me. This car has basically become my office. The last little pocket of alone time before stepping into everything else that demands my attention.the bills, emails, people, life, you know, those things. And in this moment, I am beyond exhausted. And this is not ...

Core Insights - Amazon is actively working to disrupt the healthcare industry, similar to its previous disruption of retail, through various innovative efforts and acquisitions [3][4] - The company has faced challenges in the healthcare sector due to its complexity and thin profit margins, but remains optimistic about its ability to innovate and adapt [6][5] Company Initiatives - Amazon has made significant moves in healthcare, including the acquisition of PillPack in 2018 and One Medical in 2023, as well as launching telehealth services and Amazon Pharmacy [3][4] - The company is exploring ways to "overhaul" its healthcare efforts to become more agile and innovative, as stated by Neil Lindsay, senior vice president of Amazon Health Services [4][5] Market Challenges - The healthcare sector presents numerous challenges, including thin profit margins, supply chain issues, regulatory changes, and workforce dynamics [6] - Other large companies like CVS Health, Walgreens, and Walmart have attempted to enter the healthcare space but faced significant financial hurdles, with Walmart ultimately exiting the market [7] Future Outlook - Despite leadership changes within Amazon's healthcare division, the company is expected to continue its innovative approach and adapt to the evolving healthcare landscape [5][8]

Core Insights - Doximity (DOCS) and iRhythm Technologies (IRTC) are prominent players in AI-powered healthcare, with Doximity focusing on clinician engagement and workflow, while iRhythm specializes in AI-driven cardiac monitoring [2][4] - Doximity reported fiscal 2025 revenues of $570.4 million, a 20% increase year-over-year, and a 48% rise in operating cash flow [2] - iRhythm Technologies achieved full-year 2024 revenues of $591.8 million, reflecting a 20.1% year-over-year growth [3] Company Overview - Doximity serves over 80% of U.S. physicians with a platform that includes telehealth and workflow tools [5] - iRhythm Technologies focuses on AI-driven cardiac monitoring through its Zio platform, which provides clinically validated diagnostics [5] Financial Performance - Doximity's fourth quarter of fiscal 2025 saw revenues of $138.3 million and net income of $62.5 million, with a 56% increase in free cash flow [7] - iRhythm's first-quarter 2025 revenues reached $158.7 million, a 20.3% year-over-year increase, despite a net loss of $30.7 million [10] Stock Performance - Year-to-date, Doximity's share price increased by 6.9%, while iRhythm's surged by 61.4% [6][9] - Doximity's stock performance is impacted by risks related to drug-pricing reforms and changes in pharmaceutical advertising budgets [6] AI Integration - Doximity has integrated AI into clinical workflows, notably with Doximity GPT, which automates documentation [11] - iRhythm employs AI for diagnostics through its Zio platform, supported by the ZEUS AI system for interpreting cardiac data [13] Growth Outlook - Doximity anticipates fiscal 2026 revenues between $619 million and $631 million, with adjusted EBITDA of $333-$345 million [14] - iRhythm raised its revenue outlook for the full year to $690-$700 million, with EBITDA margins projected at 7.5-8.5% [14] Investment Appeal - Doximity is viewed as a stable investment with profitability and a large user base, appealing to risk-averse investors [19] - iRhythm presents a higher-risk, higher-reward opportunity driven by innovative diagnostics and expanding clinical applications [19]